Tiago Fauth
Stock Analyst at Wells Fargo
(2.31)
# 2,686
Out of 5,058 analysts
152
Total ratings
42.24%
Success rate
-1.89%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $206.72 | +4.97% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.13 | +152.45% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $480.72 | -13.88% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.07 | +97.24% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $77.01 | -5.21% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $30.43 | +1.87% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $467.00 | -15.42% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $32.81 | +98.11% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $66.97 | +13.48% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $4.74 | +47.68% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $20.32 | +397.05% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.55 | +93.55% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $17.65 | +47.31% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $9.75 | +74.36% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $92.20 | -18.66% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $9.93 | +524.37% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $211.17 | -57.85% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $29.21 | +74.60% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $53.08 | +126.07% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $23.77 | -83.17% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.10 | +351.61% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $111.71 | +168.55% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.60 | +124.14% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.81 | +634.91% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $19.60 | +313.27% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $1.21 | +561.16% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.75 | +194.74% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.55 | +2,093.55% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $19.35 | +675.12% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $42.07 | -31.07% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.70 | +664.71% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.66 | +388.72% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.26 | +58.73% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $930.60 | -63.46% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $339.92 | -23.81% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $206.72
Upside: +4.97%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.13
Upside: +152.45%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $480.72
Upside: -13.88%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.07
Upside: +97.24%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $77.01
Upside: -5.21%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $30.43
Upside: +1.87%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $467.00
Upside: -15.42%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $32.81
Upside: +98.11%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $66.97
Upside: +13.48%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.74
Upside: +47.68%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $20.32
Upside: +397.05%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.55
Upside: +93.55%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $17.65
Upside: +47.31%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $9.75
Upside: +74.36%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $92.20
Upside: -18.66%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $9.93
Upside: +524.37%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $211.17
Upside: -57.85%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $29.21
Upside: +74.60%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $53.08
Upside: +126.07%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $23.77
Upside: -83.17%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.10
Upside: +351.61%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $111.71
Upside: +168.55%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $11.60
Upside: +124.14%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.81
Upside: +634.91%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $19.60
Upside: +313.27%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $1.21
Upside: +561.16%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.75
Upside: +194.74%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.55
Upside: +2,093.55%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $19.35
Upside: +675.12%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $42.07
Upside: -31.07%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.70
Upside: +664.71%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.66
Upside: +388.72%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.26
Upside: +58.73%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $930.60
Upside: -63.46%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $339.92
Upside: -23.81%